Andrew Elbardissi

Dr. ElBardissi joined Deerfield in 2017 to work on structured transactions in Deerfield’s Private Design Funds. Dr. ElBardissi is currently a board director on Neochord, SentreHeart, Acutus, Conventus, Farapulse, vWave, Sollis Therapeutics, and Epic Sciences.

Before joining Deerfield, Dr. ElBardissi was an early-stage life sciences investor focusing on medical technology and biotechnology and was previously an investment banker in J.P. Morgan’s healthcare practice. He received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Dr. ElBardissi has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has over 30 publications in leading peer-reviewed scientific journals, and has presented his research at numerous medical and surgical conferences.